Literature DB >> 21832933

IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation.

Donald N Forthal1, Gary Landucci, Haitao Ding, John C Kappes, Angela Wang, Irene Thung, Tran Phan.   

Abstract

OBJECTIVES: To determine the effect of IgG2 opsonization on internalization of HIV-1 virus-like particles (VLPs) by monocytes and to determine the effect of gp120 glycosylation on IgG subclass binding.
DESIGN: Fc-Fcγ receptor (FcγR) interactions are important in antibody-mediated protection from lentivirus infection. Such interactions are influenced by IgG subclass, with IgG2 having low affinity to most FcγRs. We determined the impact of IgG2 on internalization of antibody-opsonized VLPs. It is also known that gp120 glycans affect the binding and function of anti-gp120 antibodies. We determined whether binding of each IgG subclass to recombinant gp120 (rgp120) was similarly impacted by gp120 glycosylation.
METHODS: Green fluorescent protein (GFP) containing VLPs were opsonized with IgG and IgG2-depleted IgG from individuals vaccinated with rgp120 during the Vax004 vaccine trial. Opsonized VLPs were incubated with peripheral blood mononuclear cells from healthy donors (n = 46), and percentages of GFP+ monocytes were determined by flow cytometry. IgG subclass binding of pooled and individual sera to rgp120 and to deglycosylated (PNGase-treated) rgp120 was determined by ELISA.
RESULTS: IgG2 elicited by rgp120 vaccination inhibited internalization of antibody-opsonized HIV-1 VLPs by monocytes from healthy individuals (P = 2.8 × 10(-5)). We also found that both IgG2 and IgG4 bound more poorly to enzymatically deglycosylated rgp120 than to unchanged rgp120. On the contrary, IgG1 and IgG3 bound slightly better to deglycosylated rgp120.
CONCLUSION: Vaccine-induced IgG2 may adversely affect a potentially important antiviral antibody activity, and altering Env glycans might provide the means to bias the subclass response in a favorable direction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21832933     DOI: 10.1097/QAD.0b013e32834b64bd

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  17 in total

1.  Vaginal myeloid dendritic cells transmit founder HIV-1.

Authors:  Ruizhong Shen; John C Kappes; Lesley E Smythies; Holly E Richter; Lea Novak; Phillip D Smith
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

Review 2.  Systems serology for evaluation of HIV vaccine trials.

Authors:  Margaret E Ackerman; Dan H Barouch; Galit Alter
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

3.  Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors.

Authors:  Saheli Sadanand; Jishnu Das; Amy W Chung; Matthew K Schoen; Sophie Lane; Todd J Suscovich; Hendrik Streeck; Davey M Smith; Susan J Little; Douglas A Lauffenburger; Douglas D Richman; Galit Alter
Journal:  AIDS       Date:  2018-02-20       Impact factor: 4.177

4.  Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.

Authors:  M Christian Tjiam; James P A Taylor; Mazmah A Morshidi; Lucy Sariputra; Sally Burrows; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

Review 5.  Opportunities to exploit non-neutralizing HIV-specific antibody activity.

Authors:  Margaret E Ackerman; Galit Alter
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

6.  Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

Authors:  Stylianos Bournazos; Florian Klein; John Pietzsch; Michael S Seaman; Michel C Nussenzweig; Jeffrey V Ravetch
Journal:  Cell       Date:  2014-09-11       Impact factor: 41.582

7.  Conference report: "Functional Glycomics in HIV Type 1 Vaccine Design" workshop report, Bethesda, Maryland, April 30-May 1, 2012.

Authors:  Angela Malaspina; Brenda S Collins; Anne Dell; Galit Alter; Thandi M Onami
Journal:  AIDS Res Hum Retroviruses       Date:  2013-07-19       Impact factor: 2.205

Review 8.  New paradigms for functional HIV-specific nonneutralizing antibodies.

Authors:  Don Forthal; Thomas J Hope; Galit Alter
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

Review 9.  Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

Review 10.  Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design.

Authors:  Martyn A French; M Christian Tjiam; Laila N Abudulai; Sonia Fernandez
Journal:  Front Immunol       Date:  2017-07-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.